[Velaxin (venlafaxine) in the treatment of anxious depression].
Thirty patients (7 male, 23 female) mean age 35,3+/-7,8 years with anxious or anxious-apathic depression, including 24 in-patients and 6 out-patients. They were treated during 8 weeks with velaxin in dosage 225-375 mg per day. The changes of patient state evaluated with rating scales (CGI, HDRS, BDI, HADS-21). Twenty-seven patients (90%) completely underwent the course of treatment. Responders according to CGI were 25 (83,3%) cases: "improvement" - 16 (59,3%), "apparent improvement" - 9 (33,3%); "minor improvement" - 2 (7,4%) patients. The complete reduction of depressive symptoms was recorded in 33,3% of cases. The safety of velaxin in moderate therapeutic doses as well as improvement of laboratory and instrumental characteristics of somatic state was confirmed.
Il'ina
N A
NA
D000328:Adult; D000368:Aged; D018687:Antidepressive Agents, Second-Generation / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001008:Anxiety Disorders / Q000175:diagnosis / Q000188:drug therapy*; D003511:Cyclohexanols / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003863:Depression / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007297:Inpatients; D008297:Male; D008875:Middle Aged; D010045:Outpatients; D017367:Selective Serotonin Reuptake Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D016896:Treatment Outcome; D000069470:Venlafaxine Hydrochloride
D018687:Antidepressive Agents, Second-Generation; D003511:Cyclohexanols; D017367:Selective Serotonin Reuptake Inhibitors; D000069470:Venlafaxine Hydrochloride